title: Anti-tumor necrosis factor alpha switching in rheumatoid arthritis and juvenile chronic arthritis.
authors.forename: Ennio Giulio
authors.initials: EG
authors.lastname: Favalli
authors.forename: Marco
authors.initials: M
authors.lastname: Arreghini
authors.forename: Cristina
authors.initials: C
authors.lastname: Arnoldi
authors.forename: Benedetta
authors.initials: B
authors.lastname: Panni
authors.forename: Antonio
authors.initials: A
authors.lastname: Marchesoni
authors.forename: Sergio
authors.initials: S
authors.lastname: Tosi
authors.forename: Irene
authors.initials: I
authors.lastname: Pontikaki
mesh_terms: D000328:Adult; D000911:Antibodies, Monoclonal / Q000008:administration & dosage / Q000009:adverse effects; D018501:Antirheumatic Agents / Q000008:administration & dosage* / Q000009:adverse effects; D001171:Arthritis, Juvenile / Q000188:drug therapy*; D001172:Arthritis, Rheumatoid / Q000188:drug therapy*; D000068800:Etanercept; D005260:Female; D006801:Humans; D007074:Immunoglobulin G / Q000008:administration & dosage* / Q000009:adverse effects; D000069285:Infliximab; D008297:Male; D008875:Middle Aged; D018124:Receptors, Tumor Necrosis Factor / Q000008:administration & dosage*; D014409:Tumor Necrosis Factor-alpha / Q000037:antagonists & inhibitors*
chemical_list: D000911:Antibodies, Monoclonal; D018501:Antirheumatic Agents; D007074:Immunoglobulin G; D018124:Receptors, Tumor Necrosis Factor; D014409:Tumor Necrosis Factor-alpha; D000069285:Infliximab; D000068800:Etanercept